{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-036359","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2022-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.039632+00:00","generated_at":"2026-06-26T21:09:31.834638+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced","bullets":["Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.","Cash and equivalents $5.7M at Dec 31, 2021; $16M gross IPO proceeds in Feb 2022 not included.","Phase 1a trial for NXP800 (HSF1 inhibitor) initiated Dec 2021; IND-enabling studies for NXP900 ongoing.","Michael Carson appointed VP of Finance, replacing interim CFO Uri Ben-Or; Carson is a CPA with biotech finance experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-036359","json":"https://secwatch.observer/filing/0001104659-22-036359.json","markdown":"https://secwatch.observer/filing/0001104659-22-036359.md","text":"https://secwatch.observer/filing/0001104659-22-036359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/tm229925d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:09:31.834638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a7afe9f4d","claim":"Michael Carson was appointed as Vice President of Finance at Nuvectis Pharma, Inc..","evidence_excerpt":"Michael Carson, who recently joined Nuvectis as Vice President of Finance, is replacing Uri Ben-Or","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President of Finance"}],"fact_type":"executive_change"},{"claim_id":"6c23148a9f","claim":"Uri Ben-Or departed as Interim Chief Financial Officer at Nuvectis Pharma, Inc..","evidence_excerpt":"Uri Ben-Or who served as the Company's Interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"replaced"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}